Emet Surgical is redefining minimally invasive surgery with ESP – the Enhanced Surgical Precision system, an AI/ML-powered platform that provides real-time surgical guidance and cancerous tissue recognition. Founded by cancer survivor and tech entrepreneur Bob Witkow, and developed in consultation with experienced surgeons, ESP supports—rather than replaces—surgeons’ expertise. It delivers real-time, data-driven insights on the surgical video feed, enhancing precision and decision-making. Emet Surgical helps surgeons reduce complications and reoperations—persistent challenges despite decades of progress in surgical tools and techniques. The company also aims to reverse the measurable decline in incidental cancer detection since the shift from open to minimally invasive surgery. By improving visibility of critical structures and suspicious tissue in real time, ESP can improve outcomes and lower treatment costs. ESP works with any robotic or laparoscopic system and runs on proprietary technology, including IP developed internally and licensed from the University of Minnesota. Foundational research, funded largely by the U.S. National Science Foundation, gives Emet Surgical a deep scientific base with strong capital efficiency. ESP recently reached a milestone by identifying cancerous tissue in real time during video analysis—a key step toward clinical trials. Emet Surgical will launch ESP with cancer recognition, followed by advanced dissection guidance and hospital system integration. Regulatory submissions for FDA 510(k) SaMD, EU CE Mark, UKCA, and Israel AMAR are planned for Q4 2025 and Q1 2026. The company is raising capital to complete validation, secure regulatory approval, and enter the market. Investors in AI, surgical robotics, or digital health are invited to connect. Emet Surgical operates under the legal entities Emet Surgical Inc. (USA) and Emet Medical Devices Ltd. (Israel).